Savant Capital LLC Has $1.09 Million Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Savant Capital LLC increased its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 30.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,671 shares of the pharmaceutical company’s stock after buying an additional 624 shares during the period. Savant Capital LLC’s holdings in Vertex Pharmaceuticals were worth $1,087,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in VRTX. Mission Wealth Management LP increased its holdings in Vertex Pharmaceuticals by 4.5% during the 4th quarter. Mission Wealth Management LP now owns 4,893 shares of the pharmaceutical company’s stock worth $1,991,000 after purchasing an additional 212 shares in the last quarter. Certuity LLC raised its position in Vertex Pharmaceuticals by 20.2% in the 4th quarter. Certuity LLC now owns 2,580 shares of the pharmaceutical company’s stock valued at $1,050,000 after buying an additional 433 shares during the last quarter. Norden Group LLC bought a new position in Vertex Pharmaceuticals during the 4th quarter valued at $250,000. Kestra Private Wealth Services LLC boosted its holdings in Vertex Pharmaceuticals by 35.9% during the 4th quarter. Kestra Private Wealth Services LLC now owns 4,354 shares of the pharmaceutical company’s stock worth $1,772,000 after acquiring an additional 1,150 shares during the last quarter. Finally, Van ECK Associates Corp boosted its holdings in Vertex Pharmaceuticals by 13.3% during the 4th quarter. Van ECK Associates Corp now owns 174,227 shares of the pharmaceutical company’s stock worth $70,892,000 after acquiring an additional 20,466 shares during the last quarter. Institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Trading Up 0.2 %

Shares of Vertex Pharmaceuticals stock opened at $401.08 on Friday. The company’s 50-day moving average price is $409.64 and its 200-day moving average price is $399.55. The company has a current ratio of 3.99, a quick ratio of 3.78 and a debt-to-equity ratio of 0.02. Vertex Pharmaceuticals Incorporated has a 12-month low of $320.01 and a 12-month high of $448.40. The company has a market cap of $103.66 billion, a price-to-earnings ratio of 28.88, a PEG ratio of 1.88 and a beta of 0.39.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share for the quarter, topping analysts’ consensus estimates of $3.85 by $0.35. Vertex Pharmaceuticals had a net margin of 36.68% and a return on equity of 21.91%. The business had revenue of $2.52 billion for the quarter, compared to analyst estimates of $2.50 billion. During the same quarter in the prior year, the firm posted $3.33 EPS. On average, equities analysts expect that Vertex Pharmaceuticals Incorporated will post 14.95 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP Ourania Tatsis sold 354 shares of the business’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $425.70, for a total transaction of $150,697.80. Following the completion of the transaction, the executive vice president now directly owns 55,804 shares in the company, valued at $23,755,762.80. The transaction was disclosed in a document filed with the SEC, which is available through this link. In related news, EVP Ourania Tatsis sold 354 shares of the firm’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $425.70, for a total value of $150,697.80. Following the sale, the executive vice president now directly owns 55,804 shares of the company’s stock, valued at $23,755,762.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Stuart A. Arbuckle sold 4,295 shares of the business’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $420.24, for a total transaction of $1,804,930.80. Following the completion of the transaction, the chief operating officer now directly owns 75,718 shares of the company’s stock, valued at approximately $31,819,732.32. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 12,381 shares of company stock worth $5,203,249. Corporate insiders own 0.20% of the company’s stock.

Wall Street Analysts Forecast Growth

VRTX has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. raised their price target on shares of Vertex Pharmaceuticals from $390.00 to $438.00 and gave the company an “overweight” rating in a research report on Thursday, February 1st. StockNews.com raised Vertex Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday. Robert W. Baird lowered Vertex Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $325.00 price target on the stock. in a report on Wednesday, January 31st. Barclays upped their price objective on Vertex Pharmaceuticals from $446.00 to $472.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $440.00 target price on shares of Vertex Pharmaceuticals in a research note on Tuesday, February 20th. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $430.86.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.